Quarterly report pursuant to Section 13 or 15(d)

Other Comments

v3.21.2
Other Comments
9 Months Ended
Sep. 30, 2021
Unusual or Infrequent Items, or Both [Abstract]  
Other Comments Other Comments
COVID-19 Update
The Company's business remained healthy and resilient during the first nine months of 2021, despite the ongoing pandemic and the resurgence in COVID-19 cases in the third quarter of 2021. While the business continued to show strong year on year growth in revenues, and the Company expects this momentum to continue for the remainder of 2021, the COVID-19 outbreak continues to be fluid, and the extent to which the pandemic will impact the Company's business remains uncertain. The Company's 2020 revenue and earnings were negatively impacted compared to its pre-COVID-19 pandemic expectations, and the pandemic may have a negative impact on the Company's revenue and net income in the remainder of 2021. Public health officials and medical professionals have warned that a resurgence of COVID-19 cases may continue, particularly if vaccination rates do not increase or if additional potent variants emerge, which may impact the general economic recovery. The ongoing economic impacts and health concerns associated with the pandemic may continue to affect patient behavior and spending levels and could result in reduced visits and patient spending trends that adversely impact the Company's financial position and results of operations. Until the COVID-19 pandemic has been resolved as a public health crisis, it retains the potential to cause further and more severe disruption of global and national economies. The Company will continue to actively monitor the situation and may take further actions that alter its business operations as may be required by federal, state, or local authorities, or that it determines are in the best interests of its employees and patients.